FDA Inspection 1193493 — GlaxoSmithKline Biologicals
The FDA completed an inspection of GlaxoSmithKline Biologicals on Nov 8, 2022 in Singapore. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Biologics.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Nov 8, 2022
- Fiscal Year
- 2023
- Product Type
- Biologics
- Project Area
- Vaccines and Allergenic Products
- Location
- Singapore (Singapore)